Session » Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1159

Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database

10:30AM-12:30PM: Abstract Number: 1144

Autoantibody and Radiological Profiles as Prognostic Indicators in Idiopathic Inflammatory Myopathies: Insights into Mortality and Interstitial Lung Disease Development

10:30AM-12:30PM: Abstract Number: 1149

Cause-Specific Proportionate Mortality Trends in Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1163

Characteristics of Interstitial Lung Disease Progressors in an Antisynthetase Autoantibody-Positive Population

10:30AM-12:30PM: Abstract Number: 1166

Characteristics, Treatments, and Outcomes of Patients with Dermatomyositis from Two Large, Nationwide US Cohorts

10:30AM-12:30PM: Abstract Number: 1161

Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity

10:30AM-12:30PM: Abstract Number: 1151

Clinical Characterization and Recurrence Prediction Model for Immune-Mediated Necrotizing Myopathy

10:30AM-12:30PM: Abstract Number: 1145

Clinico-Immunological Profile and Treatment Outcomes of Clinically Significant Diaphragmatic Weakness in Patients with Idiopathic Inflammatory Myopathies: Results from the Largest Single-Center Cohort of 16 Cases

10:30AM-12:30PM: Abstract Number: 1154

Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 1139

Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes

10:30AM-12:30PM: Abstract Number: 1170

Computer Aided Lung Informatics, HRCT and PFT in Patients with Interstitial Lung Disease in Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1167

Construction of a Refractory Myositis Predictive Index (ReMPI) in a Cohort of Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1141

Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)

10:30AM-12:30PM: Abstract Number: 1142

Disease Trajectory in anti-MDA5 Dermatomyositis Patients Presented with Different Stage of Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 1165

Dysregulation of Peripheral Blood B-cells Is Associated with Myocarditis in Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1169

Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study

10:30AM-12:30PM: Abstract Number: 1143

Epidemiology and Spectrum of Idiopathic Inflammatory Myopathies in Individuals of Sub-Saharan Ancestry: Data from the Tertiary Care Center of the Caribbean Island of Martinique

10:30AM-12:30PM: Abstract Number: 1162

Evaluating the Efficacy of Rituximab in the Treatment of Refractory Adult Idiopathic Inflammatory Myositis Using Total Improvement Score: Data from a Real-World Multi-Centre Registry in the United Kingdom

10:30AM-12:30PM: Abstract Number: 1147

Evaluation of Adverse Pregnancy Outcomes in Patients with Inflammatory Myopathies and Ro Positivity

10:30AM-12:30PM: Abstract Number: 1146

Impact of COVID-19 on Myositis Testing Trends

10:30AM-12:30PM: Abstract Number: 1168

Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan

10:30AM-12:30PM: Abstract Number: 1150

Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies

10:30AM-12:30PM: Abstract Number: 1153

Increased Prevalence of Myositis Specific and Associated Autoantibodies in Patients with Interstitial Lung Disease of Unknown Etiology

10:30AM-12:30PM: Abstract Number: 1164

IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients

10:30AM-12:30PM: Abstract Number: 1158

Microvascular Differences Between Cancer and Non-cancer Anti-transcriptional Intermediary Factor 1 Gamma Antibody (anti-TIF1-γ) Associated Dermatomyositis Patients

10:30AM-12:30PM: Abstract Number: 1152

Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets

10:30AM-12:30PM: Abstract Number: 1156

Prevalence and Impact of Fibromyalgia in Patients with Idiopathic Inflammatory Myopathies

10:30AM-12:30PM: Abstract Number: 1140

Pulmonary Hypertension in Hospitalized Patients with Dermatomyositis & Polymyositis: A Nationwide Cohort Analysis

10:30AM-12:30PM: Abstract Number: 1157

Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases

10:30AM-12:30PM: Abstract Number: 1160

Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness

10:30AM-12:30PM: Abstract Number: 1148

Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis

10:30AM-12:30PM: Abstract Number: 1155

Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].